The AURA3 trial (NCT02151981) is an open-label, randomized trial in the second-line setting, designed to compare osimertinib with platinum-based doublet chemotherapy in patients with EGFR T790M+ locally advanced or metastatic NSCLC. Here, EGFR is linked to non-small cell lung carcinoma.